Evolving Impact of COVID‐19 on Intestinal Transplant Recipients: A Single‐Center Experience
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Colin Powers und 8 weiteren Autor:innen. Beteiligte Einrichtung: Gastro-Intestinal Rehabilitation and Transplant Center - GIRTC, Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh…. Hauptthemen laut MEDLINE: COVID-19, Organ Transplantation, Transplant Recipients, SARS-CoV-2. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
There has been significant concern about coronavirus disease 2019 (COVID‐19) among transplant recipients, particularly those who are highly immunosuppressed. Several studies have analyzed the impact of COVID‐19 on different solid organ transplant patients. However, few isolated case reports of COVID‐19 in intestinal and multivisceral transplant (ITx and MVTx) recipients are available in the literature. We report the first single‐center study evaluating the clinical course and outcome of COVID‐19 in ITx/MVTx recipients.
Methods
Adult patients (age ≥ 18 years) with confirmed cases of COVID‐19 between February 2020 and February 2024 were included in this study.
Results
Twelve of the 67 (17.9%) ITx/MVTx recipients followed at our center had COVID‐19. Seven patients (58%) were female, and the median age at diagnosis was 47 years (range: 31–68 years). The average time from transplantation to COVID‐19 was 89 months (range: 14–215 months). Nine patients (75%) required hospitalization; three of them were admitted to the intensive care unit (ICU) and required ventilator support. One patient had COVID‐19 on two different occasions. Treatment modalities consisted of monoclonal antibody treatment ( n = 5), of antiviral therapy ( n = 4), and steroid monotherapy ( n = 1). Three patients received combination therapy. Three patients (25%) developed irreversible respiratory failure and died after prolonged ventilator use.
Conclusions
Our data suggested a possible increase in the incidence of COVID‐19 in ITx and MVTx recipients with an unchanged mortality rate despite the use of vaccines and new therapeutic modalities. Further multicenter studies are needed to analyze the real impact of COVID‐19 on this unique population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastro-Intestinal Rehabilitation and Transplant Center - GIRTC, Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Colin Powers, Vikraman Gunabushanam, Ajai Khanna, Fernanda P Silveira, Ruy J Cruz
Zitieren
APA
Powers, C., Corrente, B., Joyce, J., Stein, W., Polydor, S., Gunabushanam, V., Khanna, A., Silveira, F. P., & Cruz, R. J. (2025). Evolving Impact of COVID‐19 on Intestinal Transplant Recipients: A Single‐Center Experience. Clinical Transplantation. https://doi.org/10.1111/ctr.70065
Vancouver
Powers C, Corrente B, Joyce J, Stein W, Polydor S, Gunabushanam V, et al. Evolving Impact of COVID‐19 on Intestinal Transplant Recipients: A Single‐Center Experience. Clinical Transplantation. 2025. doi:10.1111/ctr.70065
BibTeX
@article{Powers2025,
author = {Powers, Colin and Corrente, Brielle and Joyce, Jennifer and Stein, William and Polydor, Shelly and Gunabushanam, Vikraman and Khanna, Ajai and Silveira, Fernanda P and Cruz, Ruy J},
title = {Evolving Impact of COVID‐19 on Intestinal Transplant Recipients: A Single‐Center Experience},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70065}
}
EUVIMED